Abstract:Background: Although neuregulin-1 (NRG1) fusions are known to be oncogenic drivers for lung cancer, chemotherapy is the major regimen for patients with advanced non-small-cell lung cancer (NSCLC). The efficacy and survival outcomes of pemetrexed-based treatments in patients with NRG1 fusion-positive NSCLC have not been established.Methods: We enrolled NSCLC patients with NRG1 fusions based on DNA/RNA-based next-generation sequencing (NGS). The study was conducted to determine the efficacy of treatment regimens in NRG1 fusion-positive advanced NSCLC patients. We also compared the survival outcomes among advanced NSCLC patients with different subtypes of NRG1 fusions.Results: A total of 42 advanced NSCLC patients with NRG1 fusions were enrolled. The subtypes of NRG1 fusions included CD74 (24/42 [57.1%]), which was the most common fusion partner, as well as other subtypes. Twenty-six patients were tested for PD-L1 expression, 24 of whom received a pemetrexed-based regimen as first-line treatment. Five patients received afatinib-targeted therapy. Of the patients who received pemetrexed-based chemotherapy, the median progression-free survival (PFS) was longer than patients who were not treated with pemetrexed-based chemotherapy (5.0 months vs. 2.5 months, P = 0.0279). Notably, among patients treated with afatinib, the overall response rate (ORR) was 40% (2/5) and the PFS was 3 months (95% confidence interval [CI], 0.853–5.147). No differences in median overall survival [OS] (21.0 months vs. 17.0 months, P = 0.6528) were observed between the pemetrexed-based chemotherapy and non-pemetrexed-based therapy groups. Significant differences in OS were detected among patients with different NRG1 fusion subtypes (P = 0.0373).Conclusions: Pemetrexed-based treatment could be effective in advanced NSCLC Chinese patients with NRG1 fusions. The development of more effective treatment strategies is worthy of further study for patients harboring NRG1 fusions.Funding Information: This study was granted by National Natural Science Foundation of China (81873277), the Zhejiang Chinese Medical Science and Technology Foundation (2021ZQ013), Xisike-Hanson Cancer Research Foundation (Y-HS2019-20), and Huilan Public-Hanson Pharmaceutical Lung Cancer Precision Medical Research Special Fund Project Foundation (HL-HS2020-5).Declaration of Interests: All authors declare no conflicts of interest.Ethics Approval Statement: Approval of the study protocol was obtained from Nanjing University of Chinese Medicine Institutional Review Board Committee (approval number: 2022NL-KS045). Individual consent for this retrospective analysis was waived.

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

Efficacy of Pemetrexed-Based Chemotherapy in Advanced NSCLC Chinese Patients with NRG1 Fusions by TNA Sequencing: A Multicenter Study

EGFR -TKI Combined with Pemetrexed Versus EGFR -TKI Monotherapy in Advanced EGFR -mutated NSCLC: A Prospective, Randomized, Exploratory Study

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials

A Phase II Randomized Trial Evaluating Gefitinib Intercalated with Pemetrexed/platinum Chemotherapy or Pemetrexed/platinum Chemotherapy Alone in Unselected Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer.

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

Randomized controlled trial of chemotherapy plus geiftinib as ifrst-line treatment for patients with advancedEGFR mutation-positive lung adenocarcinoma

Combination of Chemotherapy and Gefitinib As First-Line Treatment for Patients with Advanced Lung Adenocarcinoma and Sensitive Egfr Mutations: A Randomized Controlled Trial

Clinical Outcomes of EGFR+/METamp+ Vs. EGFR+/METamp‐ Untreated Patients with Advanced Non‐small Cell Lung Cancer

Pemetrexed As the First-Line Therapy for Chinese Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer.